NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 PLTR
Palantir
-- 83.890 GOOG
Alphabet-C
-- 162.670 
Update
$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
3 MINUTES AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS)
3 MINUTES AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment